"Half-Life" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
| Descriptor ID |
D006207
|
| MeSH Number(s) |
G01.910.405
|
| Concept/Terms |
Half-Life- Half-Life
- Half Life
- Half-Lifes
- Halflife
- Halflifes
|
Below are MeSH descriptors whose meaning is more general than "Half-Life".
Below are MeSH descriptors whose meaning is more specific than "Half-Life".
This graph shows the total number of publications written about "Half-Life" by people in this website by year, and whether "Half-Life" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Half-Life" by people in Profiles.
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 Dec; 12(6):e70010.
-
Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat Biomed Eng. 2021 05; 5(5):387-398.
-
Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
-
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci Transl Med. 2020 01 29; 12(528).
-
Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta). J Am Assoc Lab Anim Sci. 2019 07 01; 58(4):501-509.
-
A Liquid-Chromatography High-Resolution Mass Spectrometry Method for Non-FDA Approved Benzodiazepines. J Anal Toxicol. 2019 May 01; 43(4):316-320.
-
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2019 02; 105(2):486-495.
-
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
-
Rapid Recovery Gene Downregulation during Excess-Light Stress and Recovery in Arabidopsis. Plant Cell. 2017 Aug; 29(8):1836-1863.
-
Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). J Am Assoc Lab Anim Sci. 2017 Jul 01; 56(4):443-451.